{"title":"Juvenile-Onset Recurrent Respiratory Papillomatosis","authors":"S. Sangwan, G. Smaldone","doi":"10.1089/088318701750314590","DOIUrl":"https://doi.org/10.1089/088318701750314590","url":null,"abstract":"Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP) is a condition in which benign papillomata develop and recur in the larynx. JoRRP usually develops in infancy or early childhood (median age=4 years). It is the most common benign neoplasm of the larynx in children. Common presenting symptoms include: stridor, chronic cough, recurrent pneumonia, failure to thrive, dyspnoea, dysphagia and acute respiratory distress in children with upper respiratory tract infection.. In about one third of children with JoRRP the disease spreads into the trachea and bronchi, with the risk of respiratory obstruction. Malignancy is a rare but recognised development in RRP.","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"30 1","pages":"59-62"},"PeriodicalIF":0.0,"publicationDate":"2001-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76040899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Helping Children Adhere to Asthma Treatment Regimens","authors":"H. Kelly, S. Murphy","doi":"10.1089/088318701750314545","DOIUrl":"https://doi.org/10.1089/088318701750314545","url":null,"abstract":"Nonadherence to prescribed medication is a severe problem in asthma, leading to increased health-care costs, and has been reported to be a risk factor for asthma-related mortality in children. The causes of nonadherence are multifactorial and include patient factors, communication factors, and treatment regimen factors. The relative impact of these factors on adherence as well as useful strategies for improving adherence are explored. The clinician needs to accurately assess the cause of the nonadherence to determine the appropriate intervention. The single most important factor for enhancing adherence is the development of a trusting relationship between the clinician and patient.","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"61 1","pages":"25-30"},"PeriodicalIF":0.0,"publicationDate":"2001-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87032193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dental Caries in Children with Chronic Idiopathic Urticaria in Israel","authors":"N. Segal, Y. Levy, J. Katz, Y. Danon","doi":"10.1089/088318701750314563","DOIUrl":"https://doi.org/10.1089/088318701750314563","url":null,"abstract":"Most cases of chronic urticaria in children are idiopathic. Chronic focal infections of the sinuses or oral cavity have been mentioned as a cause of chronic urticaria because of the persistent antigenic stimulation. To investigate whether children with chronic idiopathic urticaria (CIU) have a higher prevalence and total experience of dental caries than other children in Israel, oral examination was performed to determine decay, missing, filled-teeth (DMFT) scores in 25 children with CIU (mean age, 11.76 ± 3.84 years) and 50 children with perennial allergic rhinitis (PAR) (mean age, 12.57 ± 3.29 years). The results of both groups were compared with reference data from another study on 12-year-old schoolchildren in Israel (n = 762). DMFT scores were 2.84 ± 3.18 in the CIU group, 1.56 ± 1.77 in the PAR group (p = 0.07), and 2.99 ± 2.7 in the reference group (p = 0.80). The difference between the PAR and reference groups was statistically significant (p = 0.001). Twenty-eight percent of the children with CIU...","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"1 1","pages":"43-47"},"PeriodicalIF":0.0,"publicationDate":"2001-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83080462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Halász, E. Cserháti, P. Magyar, M. Kovács, K. Cseh
{"title":"Correlation Between Bronchial Hyperreactivity and Serum sTNF-R1 (60-kDa) Level in Symptom-free Childhood Asthmatic Adults and Their Offspring","authors":"A. Halász, E. Cserháti, P. Magyar, M. Kovács, K. Cseh","doi":"10.1089/088318701753436871","DOIUrl":"https://doi.org/10.1089/088318701753436871","url":null,"abstract":"Tumor necrosis factor receptors (TNF-R) are expressed on the cell membrane in asthma and soluble receptors are released into the extracellular space. The aim of the present study was to assess whet...","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"10 1","pages":"81-88"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78396580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In my opinion - Interview with the expert","authors":"B. Wray","doi":"10.1089/pai.2000.14.145","DOIUrl":"https://doi.org/10.1089/pai.2000.14.145","url":null,"abstract":"","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"80 1","pages":"55-57"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74864682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Georgitis, B. Mcwilliams, M. Cruz-Rivera, S. Fitzpatrick, Joseph A. Smith
{"title":"Effective once-daily administration of budesonide inhalation suspension by nebulizer with facemasks or mouthpieces for persistent asthma in infants and young children","authors":"J. Georgitis, B. Mcwilliams, M. Cruz-Rivera, S. Fitzpatrick, Joseph A. Smith","doi":"10.1089/088318701750314527","DOIUrl":"https://doi.org/10.1089/088318701750314527","url":null,"abstract":"This study is a retrospective analysis comparing nebulized budesonide inhalation suspension (BIS; Pulmicort Respules™, AstraZeneca, Wilmington, DE) administered once daily by facemask or mouthpiece...","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"14 1","pages":"3-13"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86090411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In My Opinion - Interview with the Expert","authors":"H. Nelson","doi":"10.1089/088318700750070484","DOIUrl":"https://doi.org/10.1089/088318700750070484","url":null,"abstract":"","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"162 1","pages":"345-348"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80265928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. DeGuzman, R. J. Rodriguez, R. Katial, M. Nelson, R. Engler
{"title":"Four-Year Experience with Serious Adverse Reactions to Intravenous γ-Globulin at a Tertiary Medical Center","authors":"R. DeGuzman, R. J. Rodriguez, R. Katial, M. Nelson, R. Engler","doi":"10.1089/088318700750070376","DOIUrl":"https://doi.org/10.1089/088318700750070376","url":null,"abstract":"Reports of the true incidence of adverse reactions to intravenous γ-globulin (IVIG) therapy are limited by the lack of studies documenting reactions in a large number of patients. The objective was to describe the frequency of serious side effects to intravenous immune globulin therapy at a major tertiary medical center between 1991 and 1995. A central pharmacy registry of a tertiary medical center was searched for all patients and doses of intravenous immune globulin therapy given in both the inpatient and outpatient setting. Records of patients were reviewed for specific details regarding an adverse reaction. Acute renal failure occurred in 2 of 194 (1%) patients and aseptic meningitis occurred in 4 of 194 (2%) patients. Renal failure occurred in 2 of 1637 (0.1%) of infusions and aseptic meningitis occurred in 5 of 1637 (0.3%) of infusions. Both cases of renal failure were adults receiving high doses (2 g/kg) of IVIG. Of the 4 patients who developed aseptic meningitis, 3 were adults and 1 was a child. A...","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"27 1","pages":"287-292"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85375841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tribute to the Allergy/Immunology Training Programs in the United States Military Services","authors":"B. Hilman","doi":"10.1089/088318700750070330","DOIUrl":"https://doi.org/10.1089/088318700750070330","url":null,"abstract":"","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"159 3 1","pages":"257-258"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83250094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aerosol Bronchodilator Delivery in Pediatric Asthma: Benefits of Metered-Dose Inhalers with Auxiliary Devices in the Ambulatory Setting","authors":"G. Rachelefsky","doi":"10.1089/088318700750070349","DOIUrl":"https://doi.org/10.1089/088318700750070349","url":null,"abstract":"Asthma is the leading chronic pediatric respiratory illness in America today. Inhaled β-agonist bronchodilator therapy is generally preferred over oral medications for children with asthma because inhaled preparations penetrate the airways more quickly and help minimize side effects. In the 1980s spacers and other auxiliary devices for metered-dose inhalers (MDIs) were developed and their efficacy, reliability, cost-effectiveness, and convenience established in clinical trials. Today, many organizations in the United States and abroad recommend MDIs with auxiliary devices for delivery of inhaled bronchodilator therapy in children. This paper looks at MDIs with auxiliary devices and nebulizers, summarizing comparative trials that have shown the benefits and equivalent efficacy of MDIs versus nebulizers in the pediatric setting. (Pediatr Asthma Allergy Immunol 2000;14[4]:259-268.)","PeriodicalId":88951,"journal":{"name":"Pediatric asthma, allergy & immunology","volume":"9 1","pages":"259-268"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74011297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}